(Q39120239)

9 September 2017

title

Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus (English)

1 reference

9 September 2017

1 reference

squamous cell carcinoma

1 reference

N Meshii

1

1 reference

9 September 2017

G Takahashi

2

1 reference

9 September 2017

S Okunaga

3

1 reference

9 September 2017

M Hamada

4

1 reference

9 September 2017

S Iwai

5

1 reference

9 September 2017

A Takasu

6

1 reference

9 September 2017

Y Ogawa

7

1 reference

9 September 2017

Y Yura

8

1 reference

9 September 2017

publication date

26 July 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

20

1 reference

9 September 2017

issue

9

1 reference

9 September 2017

page(s)

493-498

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Links between innate and cognate tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Enhancement of herpes simplex virus-induced polykaryocyte formation by 12-O-tetradecanoyl phorbol 13-acetate: association with the reorganization of actin filaments and cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Cytotoxicity tests on eye drop preparations by LDH release assay in human cultured cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

7 January 2021

Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

7 January 2021

HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.45

7 January 2021

Identifiers

DOI

10.1038/CGT.2013.45

1 reference

9 September 2017

1 reference